Scarica l'app Stockscreener
10.99
12.29%
-1.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$12.53
Aprire:
$12.54
Volume 24 ore:
3.57M
Relative Volume:
2.07
Capitalizzazione di mercato:
$1.23B
Reddito:
$577.74M
Utile/perdita netta:
$-149.78M
Rapporto P/E:
-7.85
EPS:
-1.4
Flusso di cassa netto:
$-78.21M
1 W Prestazione:
+8.38%
1M Prestazione:
-19.49%
6M Prestazione:
-5.42%
1 anno Prestazione:
-49.38%
Intervallo 1D:
$10.93
$12.99
Intervallo di 1 settimana:
$9.82
$14.97
Portata 52W:
$9.82
$22.95
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
10.99 | 1.40B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
Novocure wins FDA approval to treat pancreatic cancer with electric fields - MedTech Dive
NovoCure (NASDAQ:NVCR) Trading Down 6.5%Here's What Happened - MarketBeat
Is NovoCure (NVCR) Pricing Reflect Long Term Potential After Recent 24% Weekly Jump - simplywall.st
NovoCure (NVCR) Is Up 23.6% After Landmark FDA Nod For Optune Pax In Pancreatic Cancer - Yahoo Finance
NovoCure (NVCR) Stock Surges on Pancreatic Cancer Treatment Approval - Blockonomi
Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device - Yahoo Finance
Soleus Adds a Significant Number of Celcuity Shares - The Motley Fool
NovoCure (NVCR) Stock Soars Following Pancreatic Cancer Treatment Approval - CoinCentral
NovoCure (NVCR) stock is trending overnight — here's what you should know - MSN
What is NovoCure Limited’s book value per share2025 EndofYear Setup & Free Verified High Yield Trade Plans - mfd.ru
Approval for pancreatic cancer treatment boosts Novocure - גלובס
NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat
Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer - Yahoo Finance
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $47 | - GuruFocus
NovoCure Stock Surges After FDA Approves Optune Pax - Benzinga
Novocure Wins FDA Nod for Optune Pax Pancreatic Cancer Treatment - Medical Product Outsourcing
Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED) - Benzinga
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright By Investing.com - Investing.com India
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright - Investing.com
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Novocure (NVCR) Shares Surge on FDA Approval for Optune Pax - GuruFocus
U.S. Stock Futures Rise as Fastly and Novocure Surge - Intellectia AI
Novocure shares surge after FDA approves pancreatic cancer device By Investing.com - Investing.com South Africa
Novocure shares surge after FDA approves pancreatic cancer device - Investing.com India
Form 8-KMaterial Events - Stock Titan
First new pancreatic cancer treatment in nearly 30 years is wearable - Stock Titan
Novocure shares soar 30% after FDA nod for pancreatic cancer device - Investing.com Australia
FDA Approves Novocure's Optune Pax for Pancreatic Cancer Treatme - GuruFocus
NovoCure Ltd treatment gains FDA approval for pancreatic cancer - Traders Union
Novocure Ltd FDA Approval of Optune Pax for Pancreatic Cancer - TradingView
FDA clears Novocure (NVCR) Optune Pax for locally advanced pancreatic cancer - Stock Titan
NovoCure (NVCR) Stock Is Trending OvernightHere's What You Should Know - Bitget
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story - Sahm
HC Wainwright Has Bearish Forecast for NovoCure Q1 Earnings - Defense World
HC Wainwright Has Negative View of NovoCure FY2029 Earnings - MarketBeat
Novocure stock hits 52-week low at $10.66 By Investing.com - Investing.com South Africa
C WorldWide Group Holding A S Grows Position in NovoCure Limited $NVCR - MarketBeat
Novocure stock falls after CMS revokes billing privileges By Investing.com - Investing.com South Africa
Novocure stock falls after CMS revokes billing privileges - Investing.com
NovoCure (NASDAQ:NVCR) Sets New 52-Week LowWhat's Next? - MarketBeat
Novocure stock hits 52-week low at $10.66 - Investing.com
**NovoCure Faces CMS Billing Privileges Revocation** - TradingView
Take Profit: Is NovoCure Limited stock showing strong momentumTrade Volume Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Piper Sandler reiterates Overweight rating on NovoCure stock By Investing.com - Investing.com South Africa
Piper Sandler reiterates Overweight rating on NovoCure stock - Investing.com
Hussman Strategic Advisors Inc. Takes $1.09 Million Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR) Stock Analysis: An Investor’s Look at 81.53% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR): Investor Outlook on a 76% Potential Upside in Medical Device Innovation - DirectorsTalk Interviews
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.33%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):